



User's Manual

Trenbolone ELISA Kit



DEIA-XY43



96T



This product is for research use only and is not intended for diagnostic use.

For illustrative purposes only. To perform the assay the instructions for use provided with the kit have to be used.

Creative Diagnostics

 Address: 45-1 Ramsey Road, Shirley, NY 11967, USA

 Tel: 1-631-624-4882 (USA) 44-161-818-6441 (Europe)  Fax: 1-631-938-8221

 Email: info@creative-diagnostics.com  Web: www.creative-diagnostics.com

PRODUCT INFORMATION

Intended Use

For the determination of trace quantities of Trenbolone and/or other metabolites in human urine, blood, oral fluid.

General Description

Creative Diagnostics's Trenbolone ELISA Kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for research use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS).

Principles of Testing

Creative Diagnostics's test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution. The test can be read visually or with a microplate reader equipped with a 650 nm filter. The extent of color development is inversely proportional to the amount of drug in the sample or control. In other words, the absence of the drug in the sample will result in a dark blue/purple color, whereas the presence of the drug will result in light pink to no color development.

Reagents And Materials Provided

1. **EIA Buffer:** 40 mL (ready-to-use). Phosphate buffered saline solution with bovine serum and a preservative. Provided for dilution of drug-enzyme conjugate concentrate and samples. NOTE: Please use only the EIA Buffer that is provided with this kit lot.
2. **Wash Buffer Concentrate (10×):** 20 mL. Phosphate buffered saline solution with a surfactant. Dilute 10 fold with deionized or ultrapure water before use. Diluted wash buffer is used to wash all unbound conjugate and samples from the plate after the conjugate incubation.
3. **Substrate:** 20 mL (ready-to-use). Stabilized 3, 3', 5, 5' Tetramethylbenzidine (TMB) plus Hydrogen Peroxide (H₂O₂) in a single bottle. It is used to develop the color in the wells after washing. Light sensitive.
4. **Drug-Enzyme Conjugate:** 200 µL. Drug-horseradish peroxidase concentrate. Dilute 180× before use.
5. **Antibody Coated Plate:** A 96 well Costar plate, in strips of 8 break-away wells, coated with anti-drug antiserum. The plate is ready for use as is. Do not wash.
6. **Red Stop Solution:** 20 mL (ready-to-use). Non-acidic reagent used to stop the enzyme reaction.
7. **Qualitative QC Positive Control:** 750 µL provided (synthetic human urine). Do not dilute.

8. **Qualitative QC Negative Control:** 750 µL provided (synthetic human urine). Do not dilute.

Materials Required But Not Supplied

1. Deionized water.
2. Precision pipettes that range from 10 µL - 1000 µL and disposable tips.
3. Graduated cylinder to dilute and mix wash buffer.
4. Plate cover or plastic film to cover plate during incubation.
5. Clean glassware (i.e. test tubes) to dilute drug-enzyme conjugate.
6. Microplate reader with 650 nm filter if Red Stop is used, or a 450 nm filter if 1N HCl is used to stop the reaction. Note: It is not necessary to stop the reaction if reading immediately. Unstopped reactions should be read with a 650 nm filter.

Storage

This kit can be used until the expiration date on the label when stored refrigerated at 2-8°C. Store controls frozen if not used within 10 days. Note: Some kits require controls to be stored frozen immediately upon receipt. Reference kit label for details.

Specimen Collection And Preparation

Recommended minimum sample dilutions are listed below. These dilutions may change based on your laboratory's determination. All sample dilutions should be made in Creative Diagnostics's EIA Buffer.

- a. **Urine:** A dilution with EIA Buffer may be necessary to reduce natural background as well as bring desired cutoff concentration within the assay range. Please contact Creative Diagnostics for assistance.
- b. **Whole blood:** A dilution of 1:5 (i.e. 1 part sample to 4 parts provided EIA Buffer) is recommended. Please contact Creative Diagnostics for assistance.
- c. **Other sample types:** Please contact Creative Diagnostics for assistance.

Assay Procedure

The following test procedures can be run manually or on an automated instrument. Please contact Creative Diagnostics for assistance with protocols for automated instruments.

1. Determine the number of wells to be used.
2. Prepare the enzyme conjugate solution by diluting the 180× enzyme conjugate stock 1 to 180 in the EIA Buffer provided. Mix the solution by inversion. Do not vortex. Example: for two eight well strips, add 25 µL of the 180× enzyme conjugate stock to 4475 µL of EIA Buffer.
3. Add 20 µL of sample, laboratory calibrators and Creative Diagnostics controls to the appropriate wells in duplicate. DO NOT dilute Creative Diagnostics's positive and negative controls.
4. Add 180 µL of diluted drug-enzyme conjugate to each well. Use 8-channel pipette or 12-channel pipette for rapid addition.
5. For manual runs, mix by gently shaking plate. A microplate shaker may be used.

6. Cover plate with plastic film or plate cover and incubate at room temperature for 45 minutes.
7. During the conjugate incubation, dilute concentrated wash buffer 10 fold with deionized water (i.e. 20 mL of concentrated wash buffer plus 180 mL of deionized water). Mix thoroughly. Diluted wash buffer is stable for 5 days at room temperature or 7 days at 2-8°C.
8. Once the incubation is complete, dump or aspirate the liquid from the wells. Tap the plate on a clean lint-free towel to remove any remaining liquid in the wells.
9. Wash each well with 300 µL of diluted wash buffer. **Manual Wash:** For manual wash procedures repeat for a total of 3 washings, invert and tap dry the plate following each step. After completing the last wash step wipe the bottom of the wells with a lint-free towel to remove any liquid on the outside of the wells.
Automated Wash: If an automated plate washer is used wash the plate for a total of 5 washings with 300 µL of diluted wash buffer. It is important for the automated washer to conduct a final aspirate cycle to eliminate residual amounts of wash buffer. Residual amounts of buffer in the wells will affect assay performance. Note: DI water should never be used for the plate wash.
10. Add 150 µL of the Substrate to each well. For manual runs, use a multi-channel pipette for best results.
11. Incubate at room temperature for 30 minutes. Gently shake immediately before measuring the absorbance.
12. Add 50 µL of Creative Diagnostics's Red Stop Solution to each well to stop enzyme reaction. Mix gently before measuring the absorbance. For automated systems a 10 second shake is sufficient. Measure the absorbance at a wavelength of 650 nm. Wells should be read within 2 hours of stopping the reaction. Note: When Creative Diagnostics's Red Stop is used, it will result in a color ranging from a dark blue/purple to light pink based on the concentration of drug present. If 1 N HCl is preferred, use 50 µL per well and read plate with a 450 nm filter. All QC data is generated without using a stopping reagent. Note: When acid stop is used, OD values will approximately double as compared to the OD values obtained with Red Stop.

NOTES

1. Desiccant bag must remain in foil pouch with unused strips. Keep ziplock pouch sealed when not in use to maintain a dry environment.
2. Use clean pipette tips for the buffer, drug-enzyme conjugate, controls and samples.
3. Before pipetting a reagent, rinse the pipette tip three times with that reagent.
4. When pipetting into the wells, **DO NOT** allow the pipette tip to touch the inside of the well or any of the reagent already inside the well. This may result in cross contamination.
5. Controls and samples should be assayed in duplicate.
6. The drug-enzyme conjugate is most stable in its concentrated form. Dilute only the volume necessary for the amount of strips currently being used.
7. Before opening the drug-enzyme conjugate vial, tap the vial in an upright position to remove any liquid in the cap.
8. Before substrate addition, wipe the outside bottom of the wells with a lint-free wiper to remove dust and fingerprints.
9. Gently mix specimens and reagents before use. Avoid vigorous agitation.

Interpretation Of Results

Each laboratory should determine the cutoff level for their individual application. When possible, cutoff calibrators and/or standards should be prepared in the same matrix being tested.


Positive Result: Samples with an absorbance less than or equal to the laboratory's designated cutoff calibrator should be considered positive. All positive samples should be confirmed by a quantitative method such as GC/MS.

Negative Result: Samples with an absorbance greater than the laboratory's designated cutoff calibrator should be considered negative.

Qualitative QC Controls: The Creative Diagnostics positive and negative controls provided in the kit are for QC purposes only. The sole purpose of these controls is to verify that the test kit is performing properly. The controls are not intended for use as cutoff calibrators. The positive control is spiked at a high concentration and its approximate level can be found on the label.

Note: The kit was designed for screening purposes only. It is recommended that all suspect samples be confirmed by a quantitative method such as GC/MS or HPLC.

Typical Standard Curve



Sensitivity

Compound	I-50 in EIA Buffer
Trenbolone	0.1ng/mL
Nandrolone	0.5 ng/mL
Mesterolone	1.7 ng/mL
Testosterone	2.7 ng/mL
Boldenone	7.5 ng/mL
Epitrenbolone	16.9 ng/mL
Estradiol	17.3 ng/mL

The term I-50 is used to define the sensitivity of the test. This number is derived from a standard curve

generated with the drug in EIA Buffer. The drug concentration that shows 50% less color activity than the zero standard is considered to be the I-50.

Specificity

Compound	Compound Concentration (ng/mL)	Trenbolone Equivalents (ng/mL)	% Cross-Reactivity
Trenbolone	0.1	0.1	100%
Nandrolone	0.24	0.1	41%
Boldenone	2.9	0.1	3.4%
Testosterone	3.2	0.1	3.1%
Mesterlone	7.14	0.1	1.4%
Equilin	12.5	0.1	0.8%
Epitrenbolone	16.9	0.1	0.6%
Estradiol	17.3	0.1	0.6%
Epitestosterone	20	0.1	0.5%
17- α -Methyltestosterone	200	0.1	0.05%
Andosterone	250	0.1	0.04%
Testosterone Benzoate	250	0.1	0.04%
Pregnenolone	333	0.1	0.03%
Testosterone Enthanate	333	0.1	0.03%
Methandrostenolone	333	0.1	0.03%
Stanozolol	333	0.1	0.03%
Androstenedione	500	0.1	0.02%
Estriol	500	0.1	0.02%
Oxandrolone	500	0.1	0.02%
Dehydroepiandrosterone	1000	0.1	0.01%

Note: Trenbolone equivalents represent 50% B/B₀ assay displacement in EIA Buffer.

The compounds having cross-reactivity below 0.01% did not show any significant reaction up to 10 μ g/mL.

ALL THE FOLLOWING HAVE A CROSS-REACTIVITY <0.01%:

Acepromazine; Acetaminophen; Acetylsalicylic Acid; d-Aldosterone; Altrenogest; E-Amino-n-caproic acid; Amitriptyline; Ascorbic Acid; Benzoic Acid; Caffeine; Chlordiazepoxide; Chlorpromazine; Clenbuterol; Codeine; Corticosterone; Cortisol; Cortisone; Cotinine; 11-Dehydrocorticosterone; Dexamethasone; Dextromethorphan; Diclofenac; Dimethyl Sulfoxide; Doxepin; Ephedrine; 5 α -Estran-3 β ,17 α -diol; Estrone; Estrone 2-Sulfate; Ethyl p-amino-benzoate; Fenopropfen; Flunixin; Fluoxymesterone; Folic Acid; Folinic Acid; Furosemide; Gemfibrozil; Gentisic Acid; Glipizide; L-Glutamic Acid; Glutethimide; Glycopyrrolate; Heparin; Hippuric Acid; Hordenine; Hydrocortisone; 17- α -Hydroxyprogesterone; Ibuprofen; Imipramine; Isoxsuprine; Lidocaine; Meperidine; Metaproterenol; Methadone; Methaqualone; Methocarbamol; Methylene Blue; 6 α -Methylprednisolone; Nalorphine; Naproxen; Niacinamide; Nicotine; Nortriptyline; Orphenadrine;

Oxymetholone; Oxyphenbutazone; Penicillin G-Potassium; Penicillin G-Procaïne; Pentoxifylline; Phencyclidine (PCP); Phenothiazine; Phenylbutazone; Polyethylene Glycol; Prednisolone; Primadone; Procaïnamide; Procaïne; Progesterone Promazine; Pseudoephedrine; Pyrantel; Pyrilamine; Pyrimethamine; Quinidine; Quinine; Salbutamol; Salicylamide; Testosterone 17 β - cypionate; Salicyclic Acid; Theophylline; Thiamine; Trimethoprim, Trimpramine, Uric Acid.

Precautions

1. **DO NOT** use kits or components beyond expiration date.
2. **DO NOT** mix conjugates, EIA Buffer and plates from different kit lots.
3. **DO NOT** pipette reagents by mouth.
4. Pour Substrate out of the bottle into a clean reservoir. To prevent contamination of the substrate, **DO NOT** pipette out of the bottle.
5. All specimens should be considered potentially infectious. Exercise proper handling precautions.
6. Keep plate covered except when adding reagents, washing or reading.
7. Kit components should be refrigerated at all times when not in use.
8. Keep the controls frozen if storing longer than 10 days. Avoid repeated freeze-thaw cycles. Note: Some kits require controls to be stored frozen immediately upon receipt. Reference kit label for details.
9. Use aseptic technique when opening and removing reagents from vials and bottles.
10. **DO NOT** smoke, eat or drink in areas where specimens or reagents are being handled.
11. Do not substitute DI water for the wash step of this protocol. Use only Creative Diagnostics's wash buffer.
12. Do not use Sodium Azide with samples, standards and/or calibrators.
13. Do not reuse wells, they are for one use only.